Australia’s active vaccine safety system


Tran H, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan C, Gold M, Hissaria P, Melody S, Chunilal S, Buttery J, Clothier H, Crawford N, Phuong L, Pepperell D, Effler P, Parker C, Carter N. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study. The Lancet Western Pacific 2023;40:100894. doi:10.1016/j.lanwpc.2023.100894. [Full text]

Deng L, Lopez L, Glover C, Cashman P, Reynolds R, Macartney K, Wood N. Short-term adverse events following immunization with Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for Mpox. JAMA 2023;329:2091-2094. doi:10.1001/jama.2023.7683. [Full text]

Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA, Quinn HE, Leeb A, Cashman P, Snelling TL, Wood N, Macartney K. The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Medical Journal of Australia 2022;217:195-202. doi: 10.5694/mja2.51619. [Full text]

Hamilton E, Oversby S, Kitchener S, Ratsch A. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study. Australian and New Zealand Journal of Public Health 2022;46:738-744. doi: 10.1111/1753-6405.13300 . [Full text]

Salter SM, Li D, Trentino K, Nissen L, Lee K, Orlemann K, Peters I, Murray K, Leeb A, Deng L. Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations. Vaccines (Basel) 2022;10:2017. doi: 10.3390/vaccines10122017. [Full text]

Totterdell J, Phillips A, Glover C, Chidwick K, Marsh J, Snelling T, Macartney K. Safety of live attenuated herpes zoster vaccine in adults 70 to 79 years: a self-controlled case series analysis using primary care data from the MedicineInsight program. Vaccine 2020;38:3968-3979. doi: 10.1016/j.vaccine.2020.03.054. [Abstract]

Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford C, Snelling TL, Durrheim D, Macartney K. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open 2021;11:e043880. doi: 10.1136/bmjopen-2020-043880. [Abstract]

Glover C, Crawford N, Leeb A, Wood N, Macartney K. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. Vaccine 2020;38:4892-4900. doi: 10.1016/j.vaccine.2020.04.056. [Abstract]

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K . Comparative post-market safety profile of adjuvanted and high-dose influenza vaccines in the elderly. JAMA Open 2020;3:e204079. doi: 10.1001/jamanetworkopen.2020.4079. [Full text]

Jacoby P, Glover C, Damon C, Fathima P, Pillsbury A, Durrheim D, Gold M, Leeb A, Snelling T. Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study. BMJ Open 2020;10:e031851. doi: 10.1136/bmjopen-2019-031851. [Full text]